Abstract
Mushrooms that have been restricted to fresh markets have now entered commercial and pharmaceutical markets. However, not much research has been targeted on testing the efficiency of these commercialized mushroom powders or capsules. For the first time, efforts were made to study the bioactive properties and antimicrobial properties of four predominant mushroom capsules available for commercial purposes. Then, these commercial mushroom powders were downsized to ultrasized fine powders by sonication and then their properties were compared against the commercialized ones. The results indicated that the bioactive properties and the antioxidant properties of these powders when used as marketed capsules was very less. It was following ultrasonication assisted size reduction that the cumulative bioactivity related properties got accelerated. Micro size reduction of the mushroom powders lead to significant enhancement of antiviral properties compared to antibacterial and antifungal properties. This work demonstrates that commercialization of mushroom as powders could realize higher impact through sonication assisted ultrasizing and even nanosizing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biological Macromolecules
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
